Difference between revisions of "TRK fusions"
Jump to navigation
Jump to search
(create) |
(→Association: ref) |
||
| Line 12: | Line 12: | ||
==Association== | ==Association== | ||
*MASC. | *MASC. | ||
*Secretory breast carcinoma. | *Secretory breast carcinoma - ETV6-NTRK3.<ref name=pmid22129193>{{Cite journal | last1 = Vasudev | first1 = P. | last2 = Onuma | first2 = K. | title = Secretory breast carcinoma: unique, triple-negative carcinoma with a favorable prognosis and characteristic molecular expression. | journal = Arch Pathol Lab Med | volume = 135 | issue = 12 | pages = 1606-10 | month = Dec | year = 2011 | doi = 10.5858/arpa.2010-0351-RS | PMID = 22129193 }}</ref> | ||
==Drugs== | ==Drugs== | ||
Revision as of 05:41, 11 September 2018
TRK fusions are seen in many solid tumours and have targeted drugs.
Genes:
- TRK1
- TRK2
- TRK3
The TRK genes are tyrosine kinase receptors.
Multiple fusion partners for each gene.
Association
- MASC.
- Secretory breast carcinoma - ETV6-NTRK3.[1]
Drugs
- Merestinib.
- Larotrectinib.
- Others.
See also
References
- ↑ Vasudev, P.; Onuma, K. (Dec 2011). "Secretory breast carcinoma: unique, triple-negative carcinoma with a favorable prognosis and characteristic molecular expression.". Arch Pathol Lab Med 135 (12): 1606-10. doi:10.5858/arpa.2010-0351-RS. PMID 22129193.